LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs known as selective oestrogen receptor modulators (SERMs) have been published in a meta-analysis in The Lancet by researchers from the United Kingdom, Italy and the USA. Jack Cuzick, Professor of Epidemiology at the Wolfson Institute of Preventive Medicine, Queen Mary University of London discussed the latest findings with Peter Goodwin and explained the background and some of the issues which have prevented this effective weapon against breast cancer being widely adopted until now.
You may also like...
Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer 17 Jan, 2007 Low risk prostate cancer: scope and benefits from reducing overtreatment 24 Mar, 2013 Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer 15 Apr, 2009 First Line PARP Inhibition For Ovarian Cancer Assessed 2 Nov, 2018
- Previous story BRCA-deficient cancers respond to combination of two experimental drugs
- Next story Audio Journal of Oncology with Oncology Times, June 2013
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014